Stay updated with the latest breaking news, headlines, and in-depth stories from The Capital Today.

Get In Touch

New listing: Sai Parenterals share price settles in green

Summary

Sai Parenteral Share Price: Sai Parenterals is a Hyderabad-based pharmaceutical formulations company. Sai Parenterals shares closed the listing session on a positive note.

New listing: Sai Parenterals share price settles in green
New listing: Sai Parenterals share price settles in green

Sai Parenteral Share Price Listing: Shares of Sai Parenteral's, a diversified pharmaceutical formulation company, closed the debut trading session (Thursday, April 2, 2026) in a positive territory. On the NSE, Sai Parenterals share price closed with a gain of 1.42 per cent Rs 405.70.

On the BSE, Sai Parenterals share price settled almost flat at Rs 406.70, but with a positive bias.

Sai Parenterals Limited is a Hyderabad-based pharmaceutical formulations company.

Sai Parenterals commanded market capitalisation of Rs 1,795.44 crore at the close of the debut session, according to BSE data.

Sai Parenterals Share Price Listing

Earlier at 10 AM, Sai Parenterals shares listed with a premium of over 3 per cent against the issue price of Rs 392. The stock made its market debut at Rs 405, up 3.32 per cent from the issue price on the BSE. On the NSE, the stock started trading at Rs 400, up 2.04 per cent.

At the time of listing, Sai Parenterals' market valuation stood at Rs 1,784.84 crore on the NSE.

Sai Parenterals Share Price:  IPO Subscription  

Sai Parenterals' PO received 1.05 times subscription on the closing day of bidding on Friday, helped by institutional investors.

The IPO has a fresh issue of up to Rs 285 crore and an offer-for-sale of up to nearly 31.57 lakh equity shares.

Sai Parenterals Share Price: IPO Price Band 

Sai Parenterals' price band was fixed at Rs 372-392 per share.

Proceeds from the IPO will support the firm's expansion, particularly in strengthening its global formulations business and expanding its contract development and manufacturing organisation capabilities across both injectable products and oral solid dosage formulations.

Svatantra Microfin IPO: Ananya Birla's NBFC-MFI picks investment bankers

 

More from Markets